{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:50:53Z","timestamp":1761173453019,"version":"build-2065373602"},"reference-count":6,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.purol.2009.04.002","type":"journal-article","created":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T04:38:01Z","timestamp":1246423081000},"page":"154-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["PSA et spironolactone"],"prefix":"10.1016","volume":"20","author":[{"given":"S.","family":"Rybikowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Maurin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Deturmeny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Delaporte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Lechevallier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Coulange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.purol.2009.04.002_bib1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0026-895X(25)12955-6","article-title":"Role of the steroid 17 alpha-hydroxylase in spironolactone-mediated destruction of adrenal cytochrome P-450","volume":"40","author":"Kossor","year":"1991","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.purol.2009.04.002_bib2","first-page":"679","article-title":"Interactions m\u00e9dicamenteuses avec l\u2019\u00e9quilibre androg\u00e9nique de l\u2019homme adulte. Rapport AFU 2004","volume":"14","author":"Siberti","year":"2004","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2009.04.002_bib3","first-page":"81","article-title":"Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women","volume":"85","author":"N\u00e9gri","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.purol.2009.04.002_bib4","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/09513590400012069","article-title":"High serum prostate-specific antigen concentrations in hirsute women do not decrease with treatment by the combination of spironolactone and the contraceptive pill","volume":"19","author":"Guzelmeric","year":"2004","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.purol.2009.04.002_bib5","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0022-5347(17)67001-0","article-title":"Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate","volume":"114","author":"Walsh","year":"1975","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2009.04.002_bib6","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708709001262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708709001262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:18:35Z","timestamp":1761113915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708709001262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":6,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S1166708709001262"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2009.04.002","relation":{},"ISSN":["1166-7087"],"issn-type":[{"type":"print","value":"1166-7087"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSA et spironolactone","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2009.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}